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Abstract
Measles	is	an	acute	febrile	illness,	potentially	fatal	and	highly	contagious,	which	is	transmitted	through	the	respiratory	mode.	Fever	
combined	with	one	of	the	following:	cough,	coryza,	conjunctivitis	are	the	first	manifestations	of	the	disease.	Koplik’s	spots	may	
also	appear	on	the	buccal	mucosa	providing	an	opportunity	to	set	the	diagnosis	even	before	the	emergence	of	rash.	Rash	typically	
appears	3–4	days	after	the	onset	of	fever,	initially	on	the	face	and	behind	the	ears,	and	its	appearance	is	associated	with	the	peak	
of	the	symptoms.	Measles	affects	multiple	systems,	including	the	respiratory	system,	with	pneumonia	being	one	of	the	most	lethal	
complications.	Management	 involves	 best	 supportive	 care,	 correction	 of	 dehydration	 and	 nutritional	 deficiencies,	 treatment	 of	
secondary	bacterial	infections	and	provision	of	vitamin	A.	Importantly,	given	that	measles	present	with	lifelong	immunity	following	
infection	or	vaccination,	prevention	through	measles	vaccination	has	a cardinal	role	for	measles’	elimination.	Indeed,	public	education	
and	vaccination	led	to	an	estimated	79%	decrease	in	global	measles	deaths	from	2000	to	2015.	Nonetheless,	the	last	two	years	have	
seen	a measles	outbreak	in	several	countries,	partially	due	to	the	anti-vaccination	movement.	This	article	aims	to	present	two	cases	
of	measles	in	our	hospital	and	highlight	the	pressing	need	for	vaccination	in	order	to	eradicate	a potentially	fatal	disease.
Key words: measles,	Koplik’s	spots,	rash,	vaccination
Adv Respir Med. 2019; 87: 63–67
Introduction
Measles represents an acute and potentially 
fatal, febrile illness, affecting not only children 
but also adults [1]. Measles virus is transmitted 
through respiratory droplets or small — particle 
aerosols sustained in the air for up to 2 hours [2]. 
An incubation period of the disease lasts approxi-
mately 10 days, while its first manifestations include 
fever along with one of the three ’Cs’: cough, coryza, 
conjunctivitis. Koplik’s spots may also appear on 
the buccal mucosa providing an opportunity to set 
the diagnosis even before the appearance of rash. 
Rash typically becomes visible 3–4 days after the 
onset of fever, initially on the face and behind the 
ears [1]. Measles could also cause life-threatening 
complications affecting systems such as respiratory 
and central nervous system [1]. However, deaths 
due to measles have significantly declined during 
the last century, mainly through global vaccination 
measurements as well as improvements in socio-
economic status and health care. Of note, before 
the introduction of measles vaccination in 1963, 
an estimated 30 million cases of measles occurred 
each year leading to more than 2 million deaths [3]. 
Unfortunately, the past few years, diminishment of 
public awareness and anti-vaccination movements 
led to recent outbreaks of diseases thought to be 
eliminated, including measles [4]. Here, we report 
two cases of measles-associated pneumonia in 
adults with incomplete measles vaccination, and 
highlight the pressing need for vaccination.
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Figure 1.	Koplik	spots	at	the	left	buccal	mucosa
Figure 2.	Case	1.	Chest	CT	showing	diffuse	ground	glass	opacities	in	pulmonary	parenchyma
Case 1
A 42-year-old male, active smoker, immu-
nized against measles with only one shot in child-
hood, was admitted to our clinic complaining 
about fever up to 39,3ο C during the past seven 
days, cough, exertional dyspnea and diarrhea. 
Of note, a skin rash showed up at the face and 
expanded to the upper arms and trunk 24 hours 
before admission. The patient also complained 
about sore throat and right earache.
On admission, his vital signs were normal. 
Arterial blood gases analysis revealed: pO2 = 71, 
pCO2 = 29, pH = 7,45 and HCO3 = 23. A macer-
ate skin rash was covering the face, trunk and 
limbs, whereas Koplik’s spots were present at 
the left buccal mucosa (Fig. 1). The blood tests 
revealed thrombocytopenia (83 000) and elevat-
ed levels of LDH (538 U/L). Chest-x-ray showed 
a consolidative opacity in the right lung, next to 
the cardiac figure. 
Therapeutic treatment was administered, in-
cluding broad-spectrum antibiotics (piperacillin/ 
/tazobactam and moxifloxacin), bronchodilation 
and oxygen therapy. With regards to skin rash 
and diarrhea, according to the dermatologist’s 
and internist’s advice, preservative treatment 
was provided. Serological testing for measles 
and other viruses (Hepatitis B Virus, Hepati-
tis C Virus, Human Immunodeficiency Virus, 
Herpes simplex virus, Coxsackie, Echo, Cyto-
megalovirus, Epstein-BarrVirus) antibodies was 
performed. Testing revealed elevated titers for 
measles IgM antibodies, and PCR was positive 
for virus RNA. While hospitalized, the patient 
developed severe respiratory failure. Chest com-
puted tomography (CT) demonstrated ground 
glass opacities in both lungs, centrilobular nod-
ules in the upper lobes, mediastinal lymph nodes 
and minimum bilateral pleural effusions (Fig. 2). 
No cardiac effusion was present. Brain CT was 
normal. Treatment remained unchanged. The 
patient gradually improved and was discharged 
twelve days later in good clinical condition, 
without respiratory failure and with normal 
blood tests. 
Case 2
A 52-year-old female, active smoker (40 pack- 
-years), nonimmunized against measles virus, 
with a history of osteoporosis, hypertension, 
hyperlipidemia and gastritis, was admitted to 
hospital due to pneumonia and severe type I re-
spiratory failure.
 The patient mentioned that the symptoms 
had begun three days ago, with dry cough, fever 
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(40οC) and stomachache. She underwent gastros-
copy and the biopsy showed gastritis. Thus, pro-
ton-pump inhibitors were prescribed. A general 
practitioner also examined the patient, ordering 
cefuroxime. Afterwards, the woman complained 
about acute abdomen pain, diarrhea and rash, 
mostly on the face and upper trunk, and she was 
referred to the emergency department. At the 
emergency department, the patient had SpO2 
= 90% at FiO2 40%, 15 breaths per minute, low 
blood pressure (85/60 mm Hg) and tachycardia 
(110 beats per minute), as well as an erythema-
tous purulent rash covering the face, trunk and 
upper limbs. She was immediately resuscitated 
with crystalloids and treated with oseltamivir and 
moxifloxacin. The chestx-ray revealed pneumo-
nia bilaterally, while abdominal ultrasound was 
normal. Chest CT showed consolidation in both 
lower lobes and middle lobe and centrilobular 
nodules (Fig. 3). The patient was admitted to 
the clinic where further blood and pharyngeal 
tests, including tests for measles and other vi-
ruses were undertaken. The woman deteriorated 
twelve hours after admission and she was intu-
bated and transferred to the Intensive Care Unit. 
Measles IgM antibodies were isolated and PCR 
of the pharyngeal smear was positive for virus 
RNA. The patient recovered and to this day is 
completely healthy. 
Discussion
Measles is a  febrile, highly contagious and 
potentially fatal illness. The Paramyxoviridae 
virus (genus Morbillivirus) represents one of the 
most contagious viruses, able to survive for up to 
2 hours on fomites, including tabletops and han-
dles. Aerosolized viral particles remain suspend-
ed for prolonged periods, and a nonimmunized 
person can become infected by just walking into 
a room where an infected individual has recently 
been. Measles virus is so contagious that an es-
timated 90% of exposed nonimmunized persons 
will develop the disease [5]. 
Prodromal symptoms of cough, runny nose, 
conjunctivitis, and increasing fever appear after 
an incubation period of 10 to 12 days. Fever is 
typically high by the 4th day (39–40.5°C); diarrhea 
and vomiting may also occur [1]. The characteris-
tic morbilliform rash associated with measles ap-
pears about 14 days (range 7–21 days) from initial 
exposure. The rash begins on the face and spreads 
downward to the trunk and extremities, lasting 
for 3 to 7 days and fading in the same directional 
pattern as it appears. It comes into view initially 
as discrete red macules that become confluent. 
Koplik’s spots represent 2 to 3 mm bluish-white 
raised lesions on a red base typically occurring 
on the posterior buccal mucosa and are pathogno-
monic to measles. They appear about 2 days prior 
to the onset of rash and increase in number for 
about 4 days. Their prevalence in patients with 
measles ranges between 60% and 70% [6]. The 
presence of Koplik’s spots differentiates measles 
from similar exanthems such as roseola and rubel-
la. Other symptoms may include abdominal pain, 
sore throat, mild lymphadenopathy, headache, 
and iridocyclitis leading to photophobia [7].
Approximately 30% of subjects experience 
multiple systems complications [8]. Pneumonia 
is the most common and severe complication, oc-
curring in 3–57% of cases and accounting for most 
measles-associated morbidity and mortality [5]. 
It takes two main forms: primary measles virus 
pneumonia and secondary bacterial/viral pneu-
monia. The last is associated with immuno-
suppression caused by the virus itself. Primary 
measles pneumonia, known as Hecht’s giant cell 
pneumonia, occurs in 3–4% of infected individ-
uals, especially in immunocompromised [9, 10]. 
Secondary pneumonia is mainly caused by bac-
terial infections, but viral infections, especially 
by adenovirus, can occur. It has a later onset and 
is characterized by sudden exacerbation with 
symptoms and signs usually beginning 5 to 10 
days after the rash [5]. Chest radiographic findings 
are not disease-specific and include ground glass 
opacity, consolidation, nodules, micronodules, 
Figure 3.	Case	2.	Chest	CT	demonstrating	centrilobular	nodules,	areas	of	consolidation	and	atelectasis,	as	well	as	bilateral	pleural	effusion
Advances in Respiratory Medicine 2019, vol. 87, no. 1, pages 63–67 
66 www.journals.viamedica.pl
and tree-in-bud opacities, interlobular septal 
thickening, bronchial and/or bronchiolar wall 
thickening [6]. Atypical measles pneumonia is 
more severe and presents the patients with lob-
ular or segmental infiltration with hilar lymph-
adenopathy and frequently pleural effusion [11]. 
Other complications of the respiratory tract 
include laryngo-tracheobronchitis (croup) and 
otitis media [8]. Permanent hearing loss may occur 
in children who develop otitis as a result of mea-
sles. A rare, delayed complication of measles is 
subacute sclerosing panencephalitis (SSPE), a fatal 
neurological disease caused by persistence of the 
virus in the central nervous system. SSPE develops 
7 to 10 years after recovery from clinical measles 
and causes a slow, progressive, demyelination of 
areas in the brain. The initial signs of SSPE include 
decreased school performance and behavioral 
changes. SSPE later progresses to myoclonic sei-
zures and eventually to a vegetative state [7, 12].
Clinical diagnosis of measles is determined 
by the presence of all of the following: 1) gener-
alized maculopapular rash for 3 days, 2) fever of 
38.3 °C, and 3) cough, coryza, or conjunctivitis. 
Laboratory criteria for diagnosis do not require 
epidemiologic confirmation and include any of 
the following: a positive serologic test for measles 
IgM, documentation of seroconversion by a sig-
nificant rise in measles IgG level, or identification 
of measles virus RNA by PCR [7]. 
 Treatment is supportive and includes mon-
itoring and management of fever, dehydration, 
and other discomforts and complications. Low 
vitamin A levels are associated with higher rates 
of complications and increased mortality from 
measles. Basing on the World Health Organization 
recommendations, CDC advises treatment with 
vitamin A  for all children with acute measles. 
Vitamin A should be administered once daily par-
enterally or for 2 days orally at age-specific doses 
(50,000 IU for infants < 6 months old; 100,000 
IU for infants 6 to 12 months old; 200,000 IU for 
children 12 months old). A third age-specific dose 
is recommended 2 to 4 weeks later for children 
who have clinical signs and symptoms of vitamin 
A deficiency [9).
 Given that measles is highly contagious and 
potentially fatal, vaccination seems to be crucial. 
Before the introduction of measles vaccines, 
the measles virus had been infecting 95–98% 
of children by the age of 18, and measles was 
considered an inevitable rite of passage [8]. The 
measles vaccine was first recommended as a sin-
gle dose vaccine. However, measles outbreaks 
among schoolaged children who received one 
dose of measles vaccine prompted changes in 
recommendations from a single-dose vaccine to 
two doses of measles-containing vaccine, pref-
erably Measles-Mumps-Rubella (MMR) vaccine 
[13]. In 2005, a  combined measles, mumps, 
rubella, and varicella vaccine was licensed as 
the quadrivalent MMRV [14]. Both contain the 
same Edmonston-Enders measles vaccine and 
convey equal immunity against measles. Vacci-
nation with either MMR or MMRV causes a mild 
infection. The resulting efficacy is 93% to 95% 
after 1 immunization and 98% to 99% after two 
doses. Secondary vaccine failure/waning immu-
nity is rare. MMR and MMRV are each licensed 
for use in infants older than 12 months. MMR 
may be administered to older adolescents and 
adults; however, MMRV is only approved up to 
the age of 12 [14]. Vaccination against measles 
is not recommended prior to 12 months of age 
due to poor immune response to the vaccine 
that may be at least partly owing to interference 
from circulating maternal antibodies. In outbreak 
conditions or before international travel, one dose 
of MMR vaccine may be given to infants prior to 
travel or within 72 hours of exposure or potential 
exposure. Any dose of the measles vaccine given 
before 12 months of age does not count as part of 
the two-dose series [14]. 
Despite these recommendations, parental 
concerns about vaccine safety issues, including 
a debunked-claim of a connection between vac-
cines and autism, have led to the anti-vaccination 
movement. However, there is evidence that MMR 
does not increase the risk of autism even in high-
risk children [15]. On the contrary, there is an 
urgent need for vaccination, as the virus causes 
life-threatening complications and is highly 
contagious. Measles presents even higher basic 
reproductive numbers for a directly transmitted 
pathogen than smallpox or influenza and thus it is 
estimated that there is a need of 89-94% levels of 
population immunity to achieve significant mea-
sles elimination [1]. Increased public awareness 
and vaccination are indispensable so as to avoid 
new measles outbreaks.
Conclusion
Measles represents an acute and potentially 
fatal, febrile illness, affecting not only children 
but also adults. Vaccination and improvement of 
health services led to significant reductions in 
deaths due to measles during the last century. 
However, the last years have seen the emergence 
of an anti-vaccination movement. This has led 
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to measles outbreaks and to the re-emergence 
of life-threatening complications. Thus, there is 
a pressing need for public education to increase 
disease awareness and highlight the importance 
of vaccination. Measles presents high basic re-
productive numbers for a directly transmitted 
pathogen and thus it is estimated that popula-
tion immunity should reach levels above 90% to 
achieve significant measles elimination. It’s in 
clinician’s hands to reverse this anti-vaccination 
movement. Further reports on new measles’ cases 
are needed.
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